Evidence map›Paper›PMID 40295530›Full record

ArticleScientific reports2025

MuSK is a substrate for CaMK2β but this interaction is dispensable for MuSK activation in vivo.

Jakob J Prömer, Sara Wolske, Perrine Castets, Geeske M van Woerden, Cinzia Barresi, Kevin C O'Connor, Ruth Herbst

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jakob J PrömerInstitute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, 1090, Austria.
Sara WolskeInstitute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, 1090, Austria.
Perrine CastetsDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1 rue Michel Servet, Geneva, CH-1211, Switzerland.
Geeske M van WoerdenDepartments of Clinical Genetics, ENCORE center of expertise, Erasmus, Rotterdam, 3015 GD, MC, The Netherlands.
Cinzia BarresiInstitute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, 1090, Austria.
Kevin C O'ConnorDepartments of Neurology, Yale School of Medicine, New Haven, Connecticut, 06511, USA.
Ruth HerbstInstitute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, 1090, Austria. ruth.herbst@meduniwien.ac.at.

Funding

Austrian Science Fund P31199-B27Nederlandse Organisatie voor Wetenschappelijk Onderzoek 016.Vidi.188.014Österreichische Austauschdienst Marietta-BlauSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung PCEFP3_181102
6 · The paper itself

Abstract

The neuromuscular junction (NMJ) is the unique interface between lower motor neurons and skeletal muscle fibers and is indispensable for muscle function. Tight control of its localized formation at the center of every muscle fiber, and maintenance throughout lifetime are sustained by muscle-specific kinase (MuSK). MuSK acts as central regulator of acetylcholine receptor clustering at the postsynapse. Localized and temporally controlled signaling of MuSK is primarily achieved by tyrosine autophosphorylation and inhibition thereof. Previous investigations suggested serine phosphorylation of the activation domain as an additional modulator of MuSK activation. Here we identified calcium/calmodulin dependent protein kinase II (CaMK2) and in particular CaMK2β as novel catalyst of MuSK activation and confirmed its capability to phosphorylate MuSK in heterologous cells. However, whereas CaMK2β absence in muscle cells reduced AChR clustering, MuSK phosphorylation was unchanged. Accordingly, we ruled out MuSK phosphorylation as the cause of synapse fragmentation in a mouse model for myotonic dystrophy type 1, in which the muscle-specific splice-variant of CaMK2β is missing, or as the cause of ataxia or delayed muscle development in CaMK2β knockout animals. Histological characterization of muscles of CaMK2β knockout mice indicated specific roles of CaMK2β in fast glycolytic versus slow oxidative muscle. Taken together, our data shows that MuSK can be phosphorylated by CaMK2β, but loss of CaMK2β is likely compensated by other CaMK2 paralogs at the NMJ.

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2Receptor Protein-Tyrosine KinasesReceptors, CholinergicAnimalsHumansMiceMice, KnockoutMuscle, SkeletalNeuromuscular JunctionPhosphorylationCalcium-Calmodulin-Dependent Protein Kinase Type 2Camk2b protein, mouseMuSK protein, mouseReceptor Protein-Tyrosine KinasesReceptors, Cholinergic

Identifiers

PMID40295530
PMCPMC12037915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.